Company profile KALV
There is not enough data for KalVista Pharmaceuticals - plasma kallikrein inhibitors to provide analysis
There is not enough data for KalVista Pharmaceuticals - plasma kallikrein inhibitors to provide correlation calculation
There is not enough data for KalVista Pharmaceuticals - plasma kallikrein inhibitors to provide analysis
After 39 days of this quarter the interest is at 129.0. Based on that we can calculate that during remaining 52 days it will total up to 301.0. hereditary angioedema treatment expected interest is significantly higher compared to previous quarter (+356.1%) and same quarter last year (+258.3%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 23 | 33 43.5% QoQ | 100 203.0% QoQ | 60 -40.0% QoQ |
| 2020 | 32 39.1% YoY -46.7% QoQ | 43 30.3% YoY 34.4% QoQ | 54 -46.0% YoY 25.6% QoQ | 57 -5.0% YoY 5.6% QoQ |
| 2021 | 111 246.9% YoY 94.7% QoQ | 82 90.7% YoY -26.1% QoQ | 56 3.7% YoY -31.7% QoQ | 73 28.1% YoY 30.4% QoQ |
| 2022 | 61 -45.0% YoY -16.4% QoQ | 35 -57.3% YoY -42.6% QoQ | 98 75.0% YoY 180.0% QoQ | 81 11.0% YoY -17.3% QoQ |
| 2023 | 84 37.7% YoY 3.7% QoQ | 57 62.9% YoY -32.1% QoQ | 20 -79.6% YoY -64.9% QoQ | 66 -18.5% YoY 230.0% QoQ |
| 2024 | 129 53.6% YoY 95.5% QoQ | - | - | - |
The average 5 years interest of hereditary angioedema treatment was 5.19 per week. The last year interest of hereditary angioedema treatment compared to the last 5 years has changed by 22.93%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 39.91%.
There is not enough data for small molecule protease inhibitors to provide analysis
There is not enough data for small molecule protease inhibitors to provide correlation calculation
There is not enough data for small molecule protease inhibitors to provide analysis
After 39 days of this quarter the interest is at 94.0. Based on that we can calculate that during remaining 52 days it will total up to 219.0. diabetic macular edema treatment expected interest is significantly higher compared to previous quarter (+271.2%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 56 | 0 -100.0% QoQ | 202 inf% QoQ | 279 38.1% QoQ |
| 2020 | 55 -1.8% YoY -80.3% QoQ | 203 inf% YoY 269.1% QoQ | 58 -71.3% YoY -71.4% QoQ | 137 -50.9% YoY 136.2% QoQ |
| 2021 | 57 3.6% YoY -58.4% QoQ | 50 -75.4% YoY -12.3% QoQ | 60 3.4% YoY 20.0% QoQ | 109 -20.4% YoY 81.7% QoQ |
| 2022 | 262 359.6% YoY 140.4% QoQ | 116 132.0% YoY -55.7% QoQ | 73 21.7% YoY -37.1% QoQ | 167 53.2% YoY 128.8% QoQ |
| 2023 | 250 -4.6% YoY 49.7% QoQ | 174 50.0% YoY -30.4% QoQ | 69 -5.5% YoY -60.3% QoQ | 59 -64.7% YoY -14.5% QoQ |
| 2024 | 94 -62.4% YoY 59.3% QoQ | - | - | - |
The average 5 years interest of diabetic macular edema treatment was 9.69 per week. The last year interest of diabetic macular edema treatment compared to the last 5 years has changed by 8.36%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -4.72%.
There is not enough data for Phase 3 KONFIDENT trial to provide analysis
There is not enough data for Phase 3 KONFIDENT trial to provide correlation calculation
There is not enough data for Phase 3 KONFIDENT trial to provide analysis
There is not enough data for Factor XIIa oral inhibitor program to provide analysis
There is not enough data for Factor XIIa oral inhibitor program to provide correlation calculation
There is not enough data for Factor XIIa oral inhibitor program to provide analysis
There is not enough data for HAE enzyme inhibitor to provide analysis
There is not enough data for HAE enzyme inhibitor to provide correlation calculation
There is not enough data for HAE enzyme inhibitor to provide analysis
There is not enough data for clinical stage pharmaceutical company to provide analysis
There is not enough data for clinical stage pharmaceutical company to provide correlation calculation
There is not enough data for clinical stage pharmaceutical company to provide analysis